Abstract
Aberrant Notch activation is linked to cancer since 1991 when mammalian Notch1 was first identified as part of the translocation t(7;9) in a subset of human T-cell acute lymphoblastic leukemias (T-ALL). Since then oncogenic Notch signaling has been found in many solid and hematopoietic neoplasms. Depending on tumor type Notch interferes with differentiation, proliferation, survival, cell-cycle progression, angiogenesis, and possibly self-renewal. In hematopoietic neoplasms, recent findings indicate an important role of Notch for TALL induction and progression and the pathogenesis of human T- and B-cell-derived lymphomas. Notch signaling has been identified as a potential new therapeutic target in these hematopoietic neoplasms. This review will focus on the most recent findings on Notch signaling in leukemias and lymphomas and its potential role in the maintenance of malignant stem cells.
Keywords: Notch, T-cell acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, multiple myeloma, cancer stem cells
Current Molecular Medicine
Title: Notch Signaling in Leukemias and Lymphomas
Volume: 8 Issue: 1
Author(s): Franziska Jundt, Rolf Schwarzer and Bernd Dorken
Affiliation:
Keywords: Notch, T-cell acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, multiple myeloma, cancer stem cells
Abstract: Aberrant Notch activation is linked to cancer since 1991 when mammalian Notch1 was first identified as part of the translocation t(7;9) in a subset of human T-cell acute lymphoblastic leukemias (T-ALL). Since then oncogenic Notch signaling has been found in many solid and hematopoietic neoplasms. Depending on tumor type Notch interferes with differentiation, proliferation, survival, cell-cycle progression, angiogenesis, and possibly self-renewal. In hematopoietic neoplasms, recent findings indicate an important role of Notch for TALL induction and progression and the pathogenesis of human T- and B-cell-derived lymphomas. Notch signaling has been identified as a potential new therapeutic target in these hematopoietic neoplasms. This review will focus on the most recent findings on Notch signaling in leukemias and lymphomas and its potential role in the maintenance of malignant stem cells.
Export Options
About this article
Cite this article as:
Jundt Franziska, Schwarzer Rolf and Dorken Bernd, Notch Signaling in Leukemias and Lymphomas, Current Molecular Medicine 2008; 8 (1) . https://dx.doi.org/10.2174/156652408783565540
DOI https://dx.doi.org/10.2174/156652408783565540 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Current Drug Targets Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Treatment Strategy Issues for Chronic HIV-1 Infection in Adults: The Dilemma of Life-long Antiretroviral Treatment
Current Medicinal Chemistry - Anti-Infective Agents Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Natural Sesquiterpenoids as Cytotoxic Anticancer Agents
Mini-Reviews in Medicinal Chemistry Synthesis and Anticancer Evaluation of Thiazacridine Derivatives Reveals New Selective Molecules to Hematopoietic Neoplastic Cells
Combinatorial Chemistry & High Throughput Screening MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Molecular Analysis of the In Vivo Metabolism and Biodistribution of Metabolically and Non-Metabolically Activated Combi-Molecules of the Triazene Class
Drug Metabolism Letters Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Chlorogenic Acid and Mental Diseases: From Chemistry to Medicine
Current Neuropharmacology Potential Health Benefits of Berries
Current Nutrition & Food Science The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals